Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related changes in the immune system and challenges for the development of age-specific vaccines.

Annals of medicine·2025
Same author

Role of new vaccinators/pharmacists in life-course vaccination.

Annals of medicine·2024
Same author

Burden of vaccine-preventable diseases in adults (50+) in the United States: a retrospective claims analysis.

BMC public health·2024
Same author

Capturing the Value of Vaccination within Health Technology Assessment and Health Economics-Practical Considerations for Expanding Valuation by Including Key Concepts.

Vaccines·2024
Same author

Nonstructural barriers to adult vaccination.

Human vaccines & immunotherapeutics·2024
Same author

Sustaining the momentum for adult vaccination post-COVID-19 to leverage the global uptake of life-course immunisation: A scoping review and call to action.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024
Same journal

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.

Immunotherapy·2026
Same journal

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.

Immunotherapy·2026
Same journal

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026
Same journal

Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis.

Immunotherapy·2026
Same journal

Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review.

Immunotherapy·2026
Same journal

Time-dependent prognostic impact of distant metastatic sites in small cell lung cancer: a comparative analysis of pre- and post-immunotherapy eras.

Immunotherapy·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Immunotherapy for TB.

T Mark Doherty1

  • 1Medical Affairs, GlaxoSmithKline, Brøndby, DK-2605 Copenhagen, Denmark. mark.x.doherty@gsk.com

Immunotherapy
|July 14, 2012
PubMed
Summary
This summary is machine-generated.

Tuberculosis (TB) remains a global health crisis due to Mycobacterium tuberculosis's complex persistence strategies. This review explores host-pathogen interactions and immunotherapy development for TB control.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

  • Immunology
  • Infectious Diseases
  • Microbiology

Background:

  • Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a persistent global health challenge.
  • Despite over a century of research, TB affects 2 billion people, causing nearly 2 million deaths annually.
  • M. tuberculosis employs sophisticated strategies to establish latent infections, hindering effective treatment.

Purpose of the Study:

  • To review current knowledge on Mycobacterium tuberculosis-immune system interactions.
  • To discuss how this understanding informs the design of novel immunotherapeutic strategies for TB.

Main Methods:

  • Literature review of immunological interactions between M. tuberculosis and the human host.
  • Analysis of historical and current immunotherapeutic approaches for TB.

Main Results:

  • M. tuberculosis has evolved complex mechanisms for long-term persistence within the host.
  • Understanding these mechanisms is crucial for developing effective TB control strategies.
  • Immunotherapy has shown varying success but remains a key area of research.

Conclusions:

  • Addressing M. tuberculosis's persistence strategies is essential for TB control.
  • Further research into host-pathogen interactions can guide the development of improved immunotherapies.
  • Integrated approaches combining immunotherapy, vaccination, and antibiotics are needed.